Walid M. Awni,Barry M. Bernstein,Scott C. Brun,Daniel E. Cohen,Emily O. Dumas,Sandeep Dutta,Amit Khatri,Cheri E. Klein,Rajeev M. Menon,Sven Mensing,Thomas J. Podsadecki
申请号：
US14503849
公开号：
US20150024999A1
申请日:
2014.10.01
申请国别(地区):
US
年份:
2015
代理人:
摘要：
The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.
